Seattle's AGC plots $194M investment to double production at Copenhagen site in busy year for biologics
Biologics manufacturing is an expensive and complicated process — but that hasn’t stopped some of the biopharma industry’s biggest players from making big splashes in recent years. Now, a Seattle-based CDMO is dropping a major down payment to double its presence in the field.
Citing an increased demand from global partners, Seattle-based AGC Biologics will pour $194 million into fleshing out its biologics manufacturing at its Copenhagen site, the company said late last month. The roughly 204,000-square-foot expansion in a new building will allow the global CDMO to double its capacity for work with single-use bioreactor mammalian cell-cultures.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
